|MDACC Study No:||2013-0907 (clinicaltrials.gov NCT No: NCT02029443)|
|Title:||A Phase 1/2, Multicenter, Open-label, and Dose-escalation Study of ACP-196 in Subjects with Chronic Lymphocytic Leukemia|
|Principal Investigator:||William G. Wierda|
|Study Description:||The goal of Part 1 of this clinical research study was to find the highest |
tolerable dose of ACP-196 that could be given to patients with CLL. Part 1 is
The goal of Part 2 of this study is to learn if ACP-196 can help to control
CLL. The safety of this drug is being studied in both parts.
This is the first study using ACP-196 in humans.